Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Nasopharyngeal Carcinoma 7Breast Neoplasms 4Uterine Cervical Neoplasms 3Nasopharyngeal Neoplasms 3Lung Neoplasms 3Colorectal Neoplasms 3Recurrence 2Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Squamous Non-small Cell Lung Cancer 1Squamous Non-Small Cell Lung Cancer SqNSCLC 1Solid Tumors 1Sarcoma 1Optic Nerve Glioma 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neuroblastoma 1Meningeal Carcinomatosis 1Melanoma 1Lymphoma, T-Cell 1Locally Advanced Squamous Non-small Cell Lung Cancer 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Breast Cancer Organoids 1Advanced Pancreatic Cancer 1

Interventions

Temozolomide 264Radiotherapy 119Bevacizumab 105Magnetic Resonance Spectroscopy 59Radiation 47pembrolizumab 30Irinotecan 28Surgical Procedures, Operative 23Lomustine 21Specimen Handling 19Nivolumab 19Radiosurgery 18Carmustine 18Aminolevulinic Acid 16Erlotinib Hydrochloride 15Drug Therapy 15Blood Specimen Collection 14Radiotherapy, Intensity-Modulated 13O(6)-benzylguanine 13Chemotherapy, Adjuvant 13Carboplatin 13Filgrastim 11Cyclophosphamide 11sargramostim 10poly ICLC 10atezolizumab 10Thalidomide 10Etoposide 10Ipilimumab 9Everolimus 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Glioblastoma × Endostatins × Clear all
NCT04267978 2024-10-15

Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas

Beijing Sanbo Brain Hospital

Phase 2 Recruiting
109 enrolled
CNS

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡